Mission Statement

We are a Boston-based private company with a mission to generate therapeutic antibodies to novel cancer targets and develop new cancer drugs to provide meaningful treatments and cures for patients with aggressive cancers.

About Us

CureMeta was founded in 2012 with the goal to discover novel targets and develop novel antibody therapeutic drugs to treat aggressive and metastatic cancers and provide real and meaningful benefits to patients suffering from these diseases.

Patent

We have filed patents on 11 antibodies that are specific to human cancers and not found in normal tissues. In 2019, we received a US patent on our lead therapeutic antibody, Bstrongximab, a therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.